### Analysis

Amgen Inc. reported strong first-quarter 2018 results, with revenue and earnings growth driven by new product launches and strong performance in key markets. The company's strategic initiatives, including the launch of Aimovig for migraine prevention and biosimilar products, are expected to drive future growth. However, the company faces uncertainties around generic competition and potential regulatory changes. The stock is expected to benefit from the positive earnings report and the company's strategic growth initiatives, but short-term market volatility may be influenced by ongoing regulatory uncertainties and competitive pressures.

### Conclusion

The short-term impact on Amgen Inc.'s stock price is likely to be positive due to the strong Q1 results and strategic growth initiatives. However, the stock may face short-term pressure from regulatory uncertainties and competitive pressures. The overall outlook for Amgen Inc.'s stock remains positive, but investors should monitor regulatory developments and competitive pressures.

[1]